Quest Diagnostics Inc vs Rio Tinto (ADR) — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Rio Tinto (ADR) trades at $94.78 (market cap $150.89B). The key difference: Rio Tinto (ADR) is far larger — about 5.9× Quest Diagnostics Inc's market cap, and Rio Tinto (ADR) pays the higher dividend (4.98%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Rio Tinto (ADR) for 10 Days on average.
| DGX | RIO | |
|---|---|---|
Market Cap | $25.48B | $150.89B |
Volume | 941,866 | 1,492,444 |
Sector | Health | Basic Materials |
52-Week High | $247.45 | $112.04 |
52-Week Low | $173.49 | $65.44 |
Typical Hold Time | 56 Days | 10 Days |
Enterprise Value | $31.23B | $164.24B |
Dividend Yield | 1.49% | 4.98% |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Rio Tinto is a global mining company that produces metals and minerals including iron ore, aluminium, copper, and lithium. Its operations supply materials used in construction, manufacturing, transportation, and energy systems.
Read more on RIO →